Univariate analysis of clinically significant liver injury in individuals with FA who did not receive HSCT
| Variable . | PLI∗ (n = 10) . | No PLI (n = 37) . | P value . |
|---|---|---|---|
| Sex, n (%) | .67 | ||
| Female | 6 (60) | 17 (45.9) | |
| Male | 4 (40) | 20 (54.1) | |
| Race, n (%) | |||
| Caucasian | 10 (100) | 35 (94.6) | .75 |
| African American | 0 | 0 | |
| Hispanic | 0 | 1 (2.7) | |
| Asian | 0 | 1 (2.7) | |
| Complementation group, n (%) | |||
| FANCA | 5 (55.6) | 29 (80.6) | .26 |
| Non-FANCA | 4 (44.4) | 7 (19.4) | |
| Androgen use, n (%) | |||
| Yes | 8 (80) | 35 (94.6) | .41 |
| No | 2 (20) | 2 (5.4) |
| Variable . | PLI∗ (n = 10) . | No PLI (n = 37) . | P value . |
|---|---|---|---|
| Sex, n (%) | .67 | ||
| Female | 6 (60) | 17 (45.9) | |
| Male | 4 (40) | 20 (54.1) | |
| Race, n (%) | |||
| Caucasian | 10 (100) | 35 (94.6) | .75 |
| African American | 0 | 0 | |
| Hispanic | 0 | 1 (2.7) | |
| Asian | 0 | 1 (2.7) | |
| Complementation group, n (%) | |||
| FANCA | 5 (55.6) | 29 (80.6) | .26 |
| Non-FANCA | 4 (44.4) | 7 (19.4) | |
| Androgen use, n (%) | |||
| Yes | 8 (80) | 35 (94.6) | .41 |
| No | 2 (20) | 2 (5.4) |
Persistent liver injury.